A Study of Paliperidone Palmitate 6-Month Formulation

Inclusion Criteria:

• Completed the Double-blind Phase of Study R092670PSY3015 without relapse andcontinue to be willing to be treated with paliperidone palmitate 6 month injection (PP6M)

• Must, in the opinion of the investigator, be able to continue treatment at the samedose level (moderate or higher dose) as used during the Double-blind Phase of StudyR092670PSY3015 at the time of screening for this study

• A woman of childbearing potential: a) Must have a negative pregnancy test on Day 1;b) Use contraception consistent with local regulations. A man must agree that duringthe study and for a minimum 12 months after receiving the last dose of the studyintervention: a) His female partner(s) will use highly effective method pfcontraception

• Sign an informed consent form (ICF) indicating that he or she understands thepurpose of, and procedures required for, the study and is willing to participate inthe study; and must be able to provide his or her own consent (that is, consentcannot be provided by a legal representative of the participant)

• In the opinion of the investigator, the patient would be able to participate for theduration of this study

Exclusion Criteria:

• Has any condition for which, in the opinion of the investigator, participation wouldnot be in the best interest of the participant (example, compromise the well-being)or that could prevent, limit, or confound the protocol-specified assessments

• Completed R092670PSY3015 while presenting adverse events deemed clinically relevantby the investigator, and which may interfere with safety and well-being of theparticipant

• If a man, has plans to father a child while enrolled in this study or within 12months after the last dose of study intervention. Must not, if a woman, have plansto become pregnant while enrolled in this study or within 12 months after the lastdose of study intervention